Lexology January 17, 2024
There is quiet but strong momentum in Washington to reclassify medical cannabis under the Controlled Substance Act (CSA) from a Schedule I drug to a Schedule III drug in 2024. Reclassification would represent a monumental shift in federal cannabis policy and an express acknowledgement that there are accepted medical uses for the drug. Consumers are already seeking insurance coverage for medical cannabis, and the drug’s expected reclassification may cause an explosion of coverage demands. Health plans should consider their policy toward cannabis now and prepare for the fallout.
Key takeaways
- While cannabis is currently illegal under federal law, the government signaled that cannabis may be reclassified as a drug with accepted medical use in treatment in the U.S. as...
Today's Sponsors
Today's Sponsor